ClinicalTrials.gg
Not yet recruitingNCT06265792OSAUpdated Mar 6, 2024

Efficacy of Stellate Ganglion Block in Obstructive Sleep Apnea

An interventional study of routine rehabilitation treatment and Stellate ganglion block in Obstructive Sleep Apnea, sponsored by Zeng Changhao. Not yet recruiting at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-06.

Sponsored by Zeng Changhao · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Sleep Apnea, Obstructive with a site in Korea, Republic of — 6 open to participants now, 6 under way, 1 of them phase 3. Sleep Apnea, Obstructive · Korea, Republic of.

Planned enrollment
3rd of 10
80 · median 55
Started
2024
the only one that year
No phase
7 of 16
4 open now
Registered
12th of 16
by date
Lead sponsor
1 of 16
Zeng Changhao

Among the 16 studies in Sleep Apnea, Obstructive with a site in Korea, Republic of, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 7 with no phase, and was the 12th registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

6 of the 16 studies in Sleep Apnea, Obstructive with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Sleep Apnea, Obstructive with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are:

  • Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study.
Read the detailed description

Obstructive Sleep Apnea is of increasingly high prevalence.

The goal of this clinical trial is to test the efficacy of stellate ganglion block in Obstructive Sleep Apnea. The main question it aims to answer are:

  • Can stellate ganglion block improve Obstructive Sleep Apnea? Patients were randomly divided into two groups, all provided with routine therapy. Based on this, the experimental group was given stellate ganglion block. The video fluoroscopic swallowing study was done to test the swallowing function before and after the study.
03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged over 18 years diagnosed with OSA by polysomnography
  • Patients with moderate to severe OSA (AHI > 15 events per hour)
  • Patients who have undergone continuous positive airway pressure (CPAP) treatment for at least 3 months but have not achieved satisfactory therapeutic effects
  • Patients who voluntarily agree to receive stellate ganglion block (SGB) treatment and sign the form

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of allergy or to local anesthetics or
  • Patients with severe cardiovascular, cerebrovascular, respiratory, hepatic, or renal diseases
  • Patients with a history of neck surgery or cervical spine disease
  • Patients with psychiatric disorders or other medical conditions that may affect the safety or effectiveness of SGB treatment
  • Pregnant or lactating women
  • Patients who have participated in other clinical trials within the past 3 months
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    The experimental group

    All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.The experimental group was given Stellate Ganglion Block.

    Behavioral: routine rehabilitation treatment · Procedure: Stellate ganglion block

  • Active comparator
    The control group

    All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy.

    Behavioral: routine rehabilitation treatment

Interventions

  • Behavioralroutine rehabilitation treatment

    All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy

  • ProcedureStellate ganglion block

    The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

06

What researchers measure

Primary outcomes

  1. Epworth Sleepiness Scale

    This scale measures daytime sleepiness. By scoring the level of sleepiness in different situations, it can help evaluate whether a patient has OSA or other sleep disorders.Scores range from 0-24. Higher scores indicate more severe daytime sleepiness.

    Time frame: day 1 and day 20

Secondary outcomes

  1. Apnea-Hypopnea Index

    Apnea-Hypopnea Index is a method to evaluate the severity of OSA. It calculates the number of apnea and hypopnea events per hour.

    Time frame: day 1 and day 20

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Dec 2024, 9 months later.

Of 511 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 9 months is below that.

Counting every sponsor, half of 629 studies reached it within 27 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Feb 20, 2024
StartEst.
Mar 1, 2024
Primary completionEst.
Dec 1, 2024
CompletionEst.
Dec 15, 2024
Last update
Mar 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06265792
Lead sponsor
Zeng Changhao
Responsible party
Zeng Changhao (Research Director, People's Hospital of Zhengzhou University) — Sponsor-investigator
First posted
Feb 20, 2024
Start date
Mar 1, 2024 (estimated)
Primary completion
Dec 1, 2024 (estimated)
Completion
Dec 15, 2024 (estimated)
Last update
Mar 6, 2024

Study contacts

Zhefeng Wang, Master
Contact
zhengzhouzhj@qq.com
19501376864
Weiji Zhao, Doctor
Contact
zwjww2009@163.com
17839973473
Nieto Luis, Doctor
study chair · Site Coordinator of United Medical Group located in Miami

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion